Profound Medical Corp. - common stock (PROF)
Frequently Asked Questions About Profound Medical Corp. - common stock (PROF)
Has Profound Medical Corp. received regulatory approvals?
Yes, Profound Medical Corp. has received regulatory approvals for the TULSA-PRO system in several markets, including the United States and Canada. The company has worked closely with regulatory agencies to ensure that its product meets safety and efficacy standards before introducing it to healthcare providers and patients.
How can investors learn more about Profound Medical Corp.?
Investors can learn more about Profound Medical Corp. by visiting the company's official website, where they can find detailed information about its products, technology, investor relations, and recent news. Additionally, the company regularly publishes press releases and financial reports that provide insights into its performance, strategy, and future outlook.
How does Profound Medical Corp. differ from its competitors?
Profound Medical Corp. distinguishes itself from competitors through its unique integration of MRI and ultrasound technology, enabling highly targeted treatments that enhance patient safety and efficacy. Additionally, the company's commitment to continuous innovation and adaptable solutions positions it to address the evolving needs of patients and healthcare professionals in the oncology field.
How does Profound Medical Corp. work with healthcare providers?
Profound Medical Corp. collaborates closely with healthcare providers to deliver training, support, and resources for the implementation of the TULSA-PRO system. The company focuses on building strong relationships with urologists and oncologists to ensure that they are equipped with the knowledge and skills necessary to utilize the technology effectively in treating patients.
How has the market reception been for Profound Medical Corp.'s technology?
The market reception for Profound Medical Corp.'s technology, particularly the TULSA-PRO system, has been largely positive. Physicians and healthcare institutions recognize the advantages of a less invasive treatment option for prostate cancer, contributing to a growing interest in adopting this innovative technology in clinical practices. This favorable reception is reflected in demand and partnership opportunities.
Is Profound Medical Corp. publicly traded?
Yes, Profound Medical Corp. is publicly traded on the NASDAQ under the ticker symbol 'PROF'. The company went public to raise capital for further development and commercialization of its products, allowing public investors to participate in its growth within the medical technology sector.
What are some recent milestones for Profound Medical Corp.?
Recent milestones for Profound Medical Corp. include achieving successful clinical trial results, expanding its TULSA-PRO technology into new international markets, and securing partnerships with key healthcare providers to enhance the adoption of its innovative therapies. These developments reflect the company's commitment to advancing its technology and reaching more patients in need.
What are the company's future goals?
Profound Medical Corp.'s future goals include broadening the adoption of the TULSA-PRO system both in North America and internationally, advancing its product pipeline through research and development, and enhancing partnerships within the healthcare community. The company seeks to solidify its position as a leader in the field of prostate cancer treatment and expand its impact on patient care.
What are the key benefits of the TULSA-PRO system?
The TULSA-PRO system offers several key benefits, including its ability to precisely target cancerous tissue while minimizing damage to surrounding healthy tissue, resulting in fewer side effects compared to traditional treatments. Additionally, the system provides real-time imaging and control during the therapeutic procedure, enhancing the overall precision and effectiveness of the treatment.
What challenges has Profound Medical Corp. faced?
Like many companies in the medical device sector, Profound Medical Corp. has faced challenges related to regulatory approval processes, market competition, and the need for ongoing research and development. However, the company has navigated these challenges by focusing on its strategic partnerships, investing in clinical evidence, and adapting to market demands to strengthen its position in the healthcare industry.
What does Profound Medical Corp. do?
Profound Medical Corp. is a medical device company focused on developing and commercializing innovative therapies for the treatment of prostate cancer. Their proprietary technology integrates the use of therapeutic ultrasound, magnetic resonance imaging (MRI), and real-time control systems to provide a non-invasive treatment alternative. This approach aims to destroy cancerous tissue while preserving surrounding healthy tissue, ultimately improving patient outcomes.
What is Profound Medical Corp.'s impact on patient care?
Profound Medical Corp.'s impact on patient care is centered around its innovative approach to treating prostate cancer. By offering a less invasive treatment option that aligns with patient preferences for preserving quality of life, the company strives to reduce side effects commonly associated with traditional cancer therapies. This focus enhances patient satisfaction and outcomes, ultimately reshaping the standards of care in prostate cancer treatment.
What is the company's vision?
The vision of Profound Medical Corp. is to revolutionize the treatment of localized prostate cancer through the development of innovative, minimally invasive therapeutic solutions. By focusing on patient-centric outcomes, the company aims to enhance the quality of life for patients while promoting safety and precision in cancer treatment.
What is the company’s approach to research and development?
Profound Medical Corp. emphasizes a robust approach to research and development, investing significant resources in clinical studies to validate and enhance its technology. The company aims to continually improve its product offerings by integrating advancements in medical technology, gathering feedback from healthcare providers, and prioritizing patient safety and outcomes.
What is the primary product offered by Profound Medical Corp.?
The primary product offered by Profound Medical Corp. is the TULSA-PRO system. This system utilizes MRI-guided transurethral ultrasound technology to deliver precise focal therapy to the prostate, providing an effective and minimally invasive treatment for prostate cancer while allowing for real-time imaging and control.
What is the significance of MRI in the TULSA-PRO system?
MRI is significant in the TULSA-PRO system as it provides high-resolution images that guide the treatment process in real-time. This advanced imaging capability allows physicians to visualize the prostate and surrounding tissues during the treatment, ensuring highly targeted delivery of ultrasound energy, which enhances the precision and effectiveness of the therapy while minimizing damage to healthy tissue.
What partnerships does Profound Medical Corp. have?
Profound Medical Corp. has established several strategic partnerships with leading healthcare institutions and research organizations to facilitate clinical studies, product validation, and technology adoption. These collaborations aim to enhance the deployment of the TULSA-PRO system and to share insights that can drive ongoing innovation within the field of prostate cancer treatment.
What role does technology play in Profound Medical Corp.'s products?
Technology plays a fundamental role in Profound Medical Corp.'s products by enabling the integration of advanced imaging and therapeutic techniques that enhance the precision and effectiveness of cancer treatment. The company's commitment to innovation ensures that its solutions are at the forefront of medical technology, offering safer and more effective treatment options for patients.
When was Profound Medical Corp. founded?
Profound Medical Corp. was founded in 2010. Since its inception, the company has been dedicated to advancing its proprietary technology designed to treat prostate cancer and has rapidly evolved to become a prominent player in the medical device industry specializing in ultrasound therapies for oncology.
Where is Profound Medical Corp. headquartered?
Profound Medical Corp. is headquartered in Toronto, Canada. This location not only positions the company within a vibrant healthcare and technology ecosystem but also allows easy access to the North American market, where it seeks to establish and expand its presence.
Who are the target customers for Profound Medical Corp.?
The target customers for Profound Medical Corp. are primarily urologic surgeons, hospitals, and healthcare facilities specializing in oncology treatments, particularly those focused on prostate cancer. The company's innovative technology aims to offer these healthcare providers an effective treatment alternative that can improve patient care and outcomes.
What is the current price of Profound Medical Corp. - common stock?
The current price of Profound Medical Corp. - common stock is 5.525
When was Profound Medical Corp. - common stock last traded?
The last trade of Profound Medical Corp. - common stock was at 3:59 pm EDT on April 2nd, 2025